One clinical study reported significantly increased blood levels of the Wnt/β-catenin-signaling inhibitor Sclerostin in male geriatric hip fracture patients compared to female age-matched patients, whereas the concentrations of another Wnt/β-catenin-signaling inhibitor, Dickkopf-1 were reduced (Dovjak et al., 2014). The gene discussed is SOST; the disease is hip fracture.